EBV BMLF1 (280-288) (HLA-A2) GLCTLVAML-acid

Description

EBV BMLF1 (280-288) (HLA-A2) is an immunodominant CEF control peptide that is derived from the Epstein-Barr virus (EBV).

See full description

Catalogue number crb1001453
Sequence (one letter code) GLCTLVAML-acid
Sequence (three letter code) H-Gly-Leu-Cys-Thr-Leu-Val-Ala-Met-Leu-OH
Purity >95%
Storage -20°C
Molecular Weight 919.5
References

Liechti and Roederer (2019). OMIP-060: 30-Parameter Flow Cytometry Panel to Assess T Cell Effector Functions and Regulatory T Cells. Cytometry A. PMID: 31334913

Zhang et al (2012). How much of virus-specific CD8 T cell reactivity is detected with a peptide pool when compared to individual peptides? Viruses. PMID: 23202497

Cohen (2015). Primary Immunodeficiencies Associated with EBV Disease. Curr Top Microbiol Immunol. PMID: 26424649

EBV BMLF1 (280-288) (HLA-A2) is an immunodominant CEF control peptide that is derived from the Epstein-Barr virus (EBV). EBV targets B cells, which can cause lytic infection and the consequent death of these cells. Natural killer (NK) cells, invariant (iNKT) cells, CD4T cells and CD8 T cells are essential to control the action of EBV-infected cells. EBV BMLF1 (280-288) (HLA-A2) is defined as a CEF control peptide due to its antigenic properties. Clinically, this peptide is a suitable epitope for CD8+ T cells and can be used to stimulate the release of IFNg. HLA-A2 refers to the cell HLA type that this peptide acts on.

EBV BMLF1 (280-288) (HLA-A2)

Cat No. Pack Size Price Qty

crb1001453h

0.5mg

$112.50

crb1001453j

1mg

$150.00